MKI67 and invasive breast carcinoma: A third window-of-opportunity trial reported by Kalinsky et al. in women with early stage breast cancer and a BMI ≥30 reported that in women taking 1,500 mg metformin there were no significant differences in Ki-67 for either DCIS or invasive breast cancer (98).